Patterns of on-treatment cardiac adverse events within three clinical trials of adjuvant anthracycline-based chemotherapy.

CONCLUSION: On-treatment cardiac events are not uncommon during adjuvant chemotherapy for early breast cancer. Higher dose of anthracyclines and higher body mass index are associated with a higher risk of on-treatment cardiac events. PMID: 29882200 [PubMed - as supplied by publisher]
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research